Risk factors for breakthrough invasive fungal infection during secondary prophylaxis | Zendy

Oliver A. Cornely | Zendy; Angelika Böhme | Zendy; Dietmar Reichert | Zendy; Stefan Reuter | Zendy; Georg Maschmeyer | Zendy; Johan Maertens | Zendy; Dieter Buchheidt | Zendy; Monika Paluszewska | Zendy; Dorothee Arenz | Zendy; Ullrich Bethe | Zendy; Jenny Effelsberg | Zendy; Harry Lövenich | Zendy; Michal Sieniawski | Zendy; Antje Haas | Zendy; Hermann Einsele | Zendy; Hartmut Eimermacher | Zendy; Rodrigo Martino | Zendy; Gerda Silling | Zendy; Moritz Hahn | Zendy; Sidonie Wacker | Zendy; Andrew J. Ullmann | Zendy; Meinolf Karthaus | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Risk factors for breakthrough invasive fungal infection during secondary prophylaxis

Author(s) -

Oliver A. Cornely,

Angelika Böhme,

Dietmar Reichert,

Stefan Reuter,

Georg Maschmeyer,

Johan Maertens,

Dieter Buchheidt,

Monika Paluszewska,

Dorothee Arenz,

Ullrich Bethe,

Jenny Effelsberg,

Harry Lövenich,

Michal Sieniawski,

Antje Haas,

Hermann Einsele,

Hartmut Eimermacher,

Rodrigo Martino,

Gerda Silling,

Moritz Hahn,

Sidonie Wacker,

Andrew J. Ullmann,

Meinolf Karthaus

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn027

Subject(s) - chemotherapy , medicine , neutropenia , intensive care medicine , risk factor , immunology

Intensive chemotherapy with severe neutropenia is associated with invasive fungal infections (IFIs) leading to high mortality rates. During leukaemia induction chemotherapy, IFI often prohibited further curative treatment, thus predisposing for leukaemia relapse. Continuing myelosuppressive chemotherapy after diagnosis of IFI has become feasible with the now expanding arsenal of safe and effective antifungals. Secondary prophylaxis of IFI is widely administered, but reliable data on outcome and risk factors for recurrent IFI during subsequent chemotherapy are not available. This study determines risk factors for recurrent IFI in leukaemia patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research